454 related articles for article (PubMed ID: 37832507)
1. Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.
Zappa E; Vitali A; Anders K; Molenaar JJ; Wienke J; Künkele A
Eur J Cancer; 2023 Nov; 194():113347. PubMed ID: 37832507
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
3. Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions.
Ligon JA; Wessel KM; Shah NN; Glod J
Front Immunol; 2022; 13():846346. PubMed ID: 35273619
[TBL] [Abstract][Full Text] [Related]
4. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
5. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
6. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
7. Promises and challenges of adoptive T-cell therapies for solid tumours.
Morotti M; Albukhari A; Alsaadi A; Artibani M; Brenton JD; Curbishley SM; Dong T; Dustin ML; Hu Z; McGranahan N; Miller ML; Santana-Gonzalez L; Seymour LW; Shi T; Van Loo P; Yau C; White H; Wietek N; Church DN; Wedge DC; Ahmed AA
Br J Cancer; 2021 May; 124(11):1759-1776. PubMed ID: 33782566
[TBL] [Abstract][Full Text] [Related]
8. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
9. CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
Guzman G; Reed MR; Bielamowicz K; Koss B; Rodriguez A
Curr Oncol Rep; 2023 May; 25(5):479-489. PubMed ID: 36853475
[TBL] [Abstract][Full Text] [Related]
10. [CAR-T Cells in solid tumours: present and future].
Ben Aïssa A; Niculescu MV; Migliorini D
Rev Med Suisse; 2021 May; 17(739):985-993. PubMed ID: 34009758
[TBL] [Abstract][Full Text] [Related]
11. Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
Guerra C; Kalaitsidou M; Kueberuwa G; Hawkins R; Edmondson R
Cancer Treat Rev; 2023 Dec; 121():102632. PubMed ID: 37837788
[TBL] [Abstract][Full Text] [Related]
12. Challenges and new technologies in adoptive cell therapy.
Zhang P; Zhang G; Wan X
J Hematol Oncol; 2023 Aug; 16(1):97. PubMed ID: 37596653
[TBL] [Abstract][Full Text] [Related]
13. CAR-Ts: new perspectives in cancer therapy.
Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
[TBL] [Abstract][Full Text] [Related]
14. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
[TBL] [Abstract][Full Text] [Related]
15. Adoptive CD8
Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
[TBL] [Abstract][Full Text] [Related]
16. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments.
Azizi AA; Pillai M; Thistlethwaite FC
Curr Opin Oncol; 2019 Sep; 31(5):430-438. PubMed ID: 31335828
[TBL] [Abstract][Full Text] [Related]
18. Navigating CAR-T cells through the solid-tumour microenvironment.
Hou AJ; Chen LC; Chen YY
Nat Rev Drug Discov; 2021 Jul; 20(7):531-550. PubMed ID: 33972771
[TBL] [Abstract][Full Text] [Related]
19. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
20. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
